Substance / Medication

Epoprostenol sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

58 trials linked to this intervention

58
Total Trials
13
Recruiting
18
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Heparin-induced thrombocytopenia type II in an infant with a congenital heart defect--anticoagulation during cardiopulmonary bypass with epoprostenol sodium and heparin.
von Heymann Christian, Hagemeyer Elmar, Kastrup Marc et al. · Pediatr Crit Care Med · 2006
PMID: 16738494Case Report
Intraoperative infusion of epoprostenol sodium for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.
Yamamoto Keisuke, Sakata Ryuzo, Iguro Yoshifumi et al. · Jpn J Thorac Cardiovasc Surg · 2006
PMID: 16972642Case Report
Epoprostenol sodium for treatment of pulmonary arterial hypertension.
Saito Yukihiro, Nakamura Kazufumi, Akagi Satoshi et al. · Vasc Health Risk Manag · 2015
PMID: 25999730ReviewFull text (PMC)
Microbial challenge test of a novel epoprostenol sodium formulation.
Bandilla Dirk, Goverde Marcel, Giudici Paolo et al. · Drug Des Devel Ther · 2017
PMID: 28848328OtherFull text (PMC)
Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted.
Lambert Olivier, Bandilla Dirk, Iyer Rupa et al. · Drug Des Devel Ther · 2012
PMID: 22563237OtherFull text (PMC)
Epoprostenol sodium, a prostaglandin I2, lacks tumor promoting effects in a medium-term liver carcinogenesis bioassay in rats.
Kawabe M, Hagiwara A, Yoshino H et al. · Cancer Lett · 2001
PMID: 11146218Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Epoprostenol sodium (substance)
SNOMED CT
108594006
UMLS CUI
C0354594

Clinical Data

This intervention maps to 6 entities in the Healos knowledge graph.

6
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
58
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.